SEX HORMONE-BINDING GLOBULIN MEDIATES PROSTATE ANDROGEN RECEPTOR ACTION VIA A NOVEL SIGNALING PATHWAY

Citation
Vdh. Ding et al., SEX HORMONE-BINDING GLOBULIN MEDIATES PROSTATE ANDROGEN RECEPTOR ACTION VIA A NOVEL SIGNALING PATHWAY, Endocrinology, 139(1), 1998, pp. 213-218
Citations number
49
Categorie Soggetti
Endocrynology & Metabolism
Journal title
ISSN journal
00137227
Volume
139
Issue
1
Year of publication
1998
Pages
213 - 218
Database
ISI
SICI code
0013-7227(1998)139:1<213:SHGMPA>2.0.ZU;2-U
Abstract
Estradiol (E-2) and 5 alpha-androstan-3 alpha,17 beta-diol (3 alpha-di ol) have been implicated in prostate hyperplasia in man and dogs, but neither of these steroids bind to androgen receptors (ARs). Recently, we reported that E-2 and 3 alpha-diol stimulated generation of intrace llular cAMP via binding to a complex of sex hormone-binding globulin ( SHBG) and its receptor (R-SHBG) On prostate cells. We speculated that this pathway, involving steroids normally found in the prostate, was i nvolved in the indirect activation of ARs. Using the dog as a model to test this hypothesis in normal prostate, we investigated whether E-2, 3 alpha-diol, and SHBG stimulated the production of the androgen-resp onsive protein, arginine esterase (AE), the canine equivalent of human prostate-specific antigen. In cultured dog prostate tissue preincubat ed with SHBG, E-2 and 3 alpha-diol stimulated AE activity. These effec ts were blocked by hydroxyflutamide, an AR antagonist, and by 2-methox yestradiol, a competitive inhibitor of E-2 and 3 alpha-diol binding to SHBG. In the absence of exogenous steroids and SHBG, AE also was sign ificantly increased by treatment with forskolin or 8-Bromaodenosine-cA MP. These observations support the hypothesis that in normal prostate, E-2 and 3 alpha-diol can amplify or substitute for androgens, with re gard to activation of the AR via the R-SHBG by a signal transduction p athway involving cAMP. Because both E-2 and 3 alpha-diol are involved in the pathogenesis of benign prostatic hyperplasia in dogs and implic ated in benign prostatic hyperplasia in man, antagonism of the prostat ic SHBG pathway may offer a novel and attractive therapeutic target.